৳ 0.00
Your Complete HealthCare Solution - Right Here
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.
৳ 0.00
10657
info@shukhee.com
Telecom Bhaban (Level- 12), 53/1 Box Nagar, Zoo Road, Dhaka-1216.


Quantity:
Products
Payment
Delivery
Indications
Verigat is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic
chronic HF and ejection fraction less than 45%.
Pharmacology
Vericiguat is a stimulator of soluble guanylate cyclase (sGC), an important enzyme in the nitric oxide (NO) signaling pathway. When NO binds to sGC, the enzyme catalyzes the synthesis of intracellular cyclic
guanosine monophosphate (cGMP), a second messenger that plays a role in the regulation of vascular tone, and cardiac contractility, and cardiac remodeling. Heart failure is associated with impaired synthesis of
NO and decreased activity of sGC, which may contribute to myocardial and vascular dysfunction. By directly stimulating sGC, independently of and synergistically with NO, vericiguat augments levels of
intracellular cGMP, leading to smooth muscle relaxation and vasodilation.
Dosage & Administration
Recommended Starting Dose: The recommended starting dose of Vericiguat is 2.5 mg orally once daily with food. Double the dose of Vericiguat approximately every 2 weeks to reach the target maintenance
dose of 10 mg once daily, as tolerated by the patient. For patients who are unable to swallow whole tablet, Vericiguat may be crushed and mixed with water immediately before administration or as directed by
physician.
Geriatric Patients: No dosage adjustment of Vericiguat is required in geriatric patients. No overall differences in safety or efficacy of Vericiguat were observed between patients aged 65 years and older
compared to younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Hepatic Impairment: No dosage adjustment of Vericiguat is recommended in patients with mild or moderate hepatic impairment.
Renal Impairment: No dosage adjustment of Vericiguat is recommended in patients with estimated glomerular filtration rate (eGFR) 215 mL/min/1.73m2 who are not on dialysis. Vericiguat has not been studied in
patients with eGFR <15 mL/min/1.73m2 at treatment initiation or on dialysis.
Use in Children & Adolescents: Safety and effectiveness of Vericiguat have not been established in pediatric patients.
Interaction
Other Soluble Guanylate Cyclase Stimulators: Verigat is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
PDE-5 Inhibitors: Concomitant use of Verigat with PDE-5 inhibitors is not recommended because of the potential for hypotension.
With food & others: Verigat should be taken with food. The absolute bioavailability of Verigat is 93% when taken with food.
Contraindications
Vericiguat is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.
Side Effects
Common Side effects: The most common side effects of Verigat tablet include low blood pressure & low red blood cells (Anemia).






Vericiguat tablet is used to treat adults who are experiencing a recent worsening of long-term heart failure symptoms.
N/A
